In this way, Bcl-2 is able to carry out an array of different functions that favor an aggressive phenotype in melanoma cells by promoting cell migration, cellular adaptation to an environment that recapitulates the matrix of solid tumors, and activation of fibroblast versus CAF phenotype, thus suggesting to further explore the possibility of using Bcl-2 inhibitors to reduce cancer progression. The gene discussed is BCL2; the disease is melanoma.